Diabetes therapy : research, treatment and education of diabetes and related disorders

Daily Oral Semaglutide Use in Adults with Type 2 Diabetes in Real-Life Italy

Updated

Abstract

A median treatment follow-up of 40 weeks resulted in an estimated change in glycated hemoglobin of -0.9%-points and a body weight reduction of -3.8 kg.

  • A total of 398 out of 445 eligible participants completed the study.
  • At the end of the study, 65.1% of participants achieved a glycated hemoglobin level of less than 7%.
  • 25.5% and 19.1% of participants experienced a reduction in glycated hemoglobin of at least 1%-point along with at least a 3% or 5% reduction in body weight, respectively.
  • Treatment satisfaction, as measured by the Diabetes Treatment Satisfaction Questionnaires, improved significantly.
  • No new safety signals were observed throughout the study.

Simplified

Key numbers

-0.9%-points
Reduction in
Change in from to .
-3.8 kg
Body Weight Reduction
Change in body weight from to .
65.1%
Achieved < 7%
Percentage of participants achieving < 7% at .

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Declarations. Conflict of Interest: Roberta Manti MD has received honorarium and fees for lectures from Novo Nordisk; and has participated in the clinical trials sponsored by Novo Nordisk, Eli Lilly, and Bayer. Salvatore De Cosmo has received honorarium and fees for lectures from Novo Nordisk, Eli Lilly, Boehringer, AstraZeneca, MSD, Sanofi, Daiichi Sankyo, Bayer, Guidotti. Paolo Desenzani has participated in the clinical trials sponsored by Novo Nordisk, Eli Lilly, and Sanofi. Lidia Ferrara has participated in the clinical trials sponsored Novo Nordisk. Memoli has received honorarium and fees for lectures from Novo Nordisk, Ely Lilly, AstraZeneca, Sanofi, Bruno Farmaceutici, Abbott, Roche Diagnostics, Novartis and Boehringer, and has participated in the clinical trials sponsored by Novo Nordisk. Angela Girelli has participated in the clinical trials sponsored by Novo Nordisk, Ely Lilly, and Sanofi Pharma. Giuseppe Memoli has received honorarium and fees for lectures Novo Nordisk, Ely Lilly, AstraZeneca, Sanofi, Bruno Farmaceutici, Abbott, Roche diagnostics, Novartis, and Boehringer; and has participated in the clinical trials sponsored by Novo Nordisk. Alessandro Bisio MD is an employee of Novo Nordisk S.p.a, Rome, Italy. Uffe Christian Braae PhD and Alisa Deinega MD, PhD are employees of Novo Nordisk A/S, Søborg, Denmark. Cesare Berra has received honorarium and fees for lectures from Novo Nordisk, Ely Lilly, AstraZeneca, Mundi pharma and Boehringer; and has participated in the clinical trials sponsored by Novo Nordisk Ely Lilly, Sophar and AstraZeneca. Ethical Approval: The study protocol was approved by the appropriate health authorities according to local guidelines and by an Institutional Review Board/Independent Ethics Committee. The study was conducted following Good Pharmacoepidemiology Practices and Good Pharmacovigilance Practices and in accordance with the Declaration of Helsinki. The Ethics Committees included: CET Lombardia 5, Comitato Etico delle Province di Chieti e Pescara, Comitato Etico Catania 1, Comitato Etico Lazio 2, Comitato Etico (CE) Istituti Clinici Scientifici Maugeri, Comitato Etico Casa Sollievo della Sofferenza, CER Umbria, Comitato Etico Palermo 2, Comitato Etico Interaziendale A.O. “SS. Antonio e Biagio e Cesare Arrigo” di Alessandria, Comitato Etico Indipendente Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Comitato Etico Brescia, Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana, Comitato Etico Territoriale Interaziendale, Comitato Etico Inter-aziendale Campania Sud, Comitato Etico Campania Nord, Comitato Etico Humanitas, Comitato Etico Azienda Sanitaria Locale Lecce, Comitato Etico per le sperimentazioni cliniche della provincia de Vicenza, Comitato Etico Palermo 1, Comitato Etico di Brescia, Comitato Etico Unico Regionale del Friuli Venezia Giulia, Comitato Etico Campania Centro, Comitato Etico per la Sperimentazione delle Province di Treviso e Belluno. All participants provided written informed consent prior to commencement of any study-related activity. The study is registered with ClinicalTrials.gov (NCT05230615).
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free